Open AccessImpact of sarcopenia on chemotherapy‐triggered exacerbation of interstitial lung disease in patients with non‐small cell lung cancer
Author(s) -
Kikuchi Ryota,
Takoi Hiroyuki,
Ishiwari Mayuko,
Toriyama Kazutoshi,
Kono Yuta,
Togashi Yuki,
Abe Shinji
Publication year - 2022
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.14294
Subject(s) - sarcopenia , medicine , exacerbation , lung cancer , chemotherapy , interstitial lung disease , oncology , lung , gastroenterology
Background While recent evidence has suggested that sarcopenia could predict chemotoxicity, its association with chemotherapy‐triggered interstitial lung disease (ILD) exacerbations has yet to be investigated. Thus, the present study sought to determine whether sarcopenia could predict ILD exacerbations and overall survival (OS) in patients with ILD‐complicated non‐small cell lung cancer (NSCLC). Methods From January 2010 to July 2020, 74 patients with ILD‐complicated NSCLC who received chemotherapy were retrospectively investigated. After categorizing patients according to the presence or absence of sarcopenia based on the psoas muscle index, ILD exacerbation rates and OS were evaluated. Results Among the patients in the study, 39 were included in the sarcopenia group. Moreover, 17 (22.9%) patients developed ILD exacerbations, with the sarcopenia and nonsarcopenia groups having an exacerbation rate of 33.3% and 11.4%, respectively ( p = 0.025). Multivariate analysis identified sarcopenia as an independent predictor of ILD exacerbations ( p = 0.039). Furthermore, patients with sarcopenia demonstrated a significantly shorter median OS compared to those without the same (9.2 vs. 13.3 months; p = 0.029). Conclusions Sarcopenia predicted chemotherapy‐triggered ILD exacerbation and OS in patients with ILD‐complicated NSCLC, suggesting its utility in determining treatment approaches.